

Ref. No: FOI2041
Date: 08/09/2025
Subject: Intra-vitreous injections or implants

REQUEST

1. How many of the following intra-vitreous injections/implants has your trust administered in the four-month period from May to August 2025:

Aflibercept
Bevacizumab
Brolucizumab
Dexamethasone
Faricimab
Fluocinolone acetonide
Ranibizumab - Lucentis
Ranibizumab - Biosimilar

2. Please provide the number of injections/implants by eye condition for the four-month period from May to August 2025:
Number of Injections/Implants: May to August 2025:

Treatment	Eye Conditions		
	Wet Age-Related Macular Degeneration (wAMD)	Diabetic Macular Oedema (DMO)	Retinal Vein Occlusion (RVO)
Aflibercept			
Bevacizumab			
Dexamethasone			
Faricimab			
Ranibizumab - Lucentis			
Ranibizumab - Ongavia (Ongavia, Ximluci, Byooviz, Rimmyrah)			

RESPONSE

S&O Response - We only supply one of the drugs (Dexamethasone) but this is as a kit to the ward, so we don't hold any patient detail or indication.

STHK legacy response:

These are the number of issues issued from the pharmacy department

- 1. How many of the following intra-vitreal injections/implants has your trust administered in the four-month period from May to August 2025:**

Aflibercept - 1115

Bevacizumab - 0

Brolucizumab - <5

Dexamethasone - 81

Faricimab - 863

Fluocinolone acetonide - <5

Ranibizumab – Lucentis - 0

Ranibizumab – Biosimilar - 351

<5

Due to the low number of patients which is less than five for the period, the Trust is withholding the actual number under section 40 – Personal Information of the Freedom of Information Act due to likelihood of

- 2. We do not hold information about specific indications.**